Topical tazarotene cream (0.1%) in the treatment of facial acne: an open clinical trial.

Abstract

BACKGROUND:

Tazarotene is a new 3rd generation topical acetylenic retinoid. It normalizes keratinocyte differentiation, reduces keratinocyte proliferation and decreases expression of inflammatory markers. Tazarotene was approved by U.S.F.D.A. in 1997 for acne vulgaris.

OBJECTIVES:

To evaluate the efficacy and safety of topical tazarotene 0.1% cream in the treatment of facial acne.

MATERIALS AND METHODS:

67 patients with facial acne in the age range of 13-30 years were enrolled in the study. Purposive sampling was done. Patients were treated with topical Tazarotene cream (0.1%) and were instructed to apply the medication as a thin film over the affected area in the evening once daily for 12 weeks. Follow-up was done at 2nd, 4th week, 8th week and at 12th week.

RESULTS:

Of the 67 patients, 53% got remission, 9% had good response, 34% had poor response and there was no response in 4% of the patients by 12 weeks of treatment. Among the patients, 9 (13.43%) developed mild side effects.

CONCLUSION:

Topical tazarotene cream (0.1%) is a effective and safe treatment option for acne vulgaris affecting face. It is mostly effective in grade-1 and grade-2 acne.

• Authors: A S M Zakaria, H K Paul, M A Rahman, M T Islam, A M Choudhury
• Journal: Bangladesh Medical Research Council bulletin (Bangladesh Med Res Counc Bull) Vol. 36 Issue 2 Pg. 43-6 (Aug 2010) ISSN: 0377-9238 [Print] Bangladesh
• PMID: 21473199 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Dermatologic Agents
• Nicotinic Acids
• tazarotene

Topics

• Acne Vulgaris (drug therapy)
• Adolescent
• Adult
• Dermatologic Agents (administration & dosage, adverse effects)
• Face
• Female
• Humans
• Male
• Nicotinic Acids (administration & dosage, adverse effects)
• Prospective Studies
• Severity of Illness Index
• Treatment Outcome
• Young Adult